July 18, 2023 07:16 AM EDT

CRO Syneos Health didn't hold up its end of the deal in enrollment for FSD Pharma's trial, arbitration panel finds

Katherine Lewin

News Reporter

The contract research organization Syneos Health didn’t hold up its end of the deal and use “commercially reasonable efforts” when setting up a trial for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

CRO Syneos Health didn't hold up its end of the deal in enrollment for FSD Pharma's trial, arbitration panel finds

Katherine Lewin

News Reporter

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Trump says he'll sign order on 'most-favored nation' drug price plans Monday

From deal to disaster: Drugmakers face a changed Washington as Trump embraces ‘most favored nation’ prices

Revolution’s KRAS drugs appear competitive in several lung cancer settings

AstraZeneca reports Phase 3 win for Imfinzi; Roche to build new manufacturing site in China

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges

CRO Sy­neos Health did­n't hold up its end of the deal in en­roll­ment for FSD Phar­ma's tri­al, ar­bi­tra­tion pan­el finds

News Reporter

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

CRO Syneos Health didn't hold up its end of the deal in enrollment for FSD Pharma's trial, arbitration panel finds